Recent Updates — MANE

Veradermics announced positive topline results from Part A of its registration-directed Phase 3 clinical trial (Study ‘304’) evaluating VDPHL01, an extended-release oral minoxidil formulation, in males with mild-to-moderate pattern hair loss. The study enrolled 536 patients and met all primary and secondary endpoints with high statistical significance. At Month 6, VDPHL01 demonstrated superior hair growth compared to placebo, achieving increases in non-vellus Target Area Hair Count of 28.6 hairs/cm² for once-daily dosing and 36.4 hairs/cm² for twice-daily dosing (p<0.0001). Patient-reported outcomes showed that 55.7% (once-daily) and 68.7% (twice-daily) of participants reported 'improved' or 'much improved' hair coverage versus 15.0% for placebo. The treatment was generally well-tolerated with no treatment-related serious adverse events or cardiac safety signals. Veradermics is a late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss.

Veradermics reported a net loss of $23.5 million for the quarter ended June 30, 2026, compared to a $15.6 million loss in the prior year period. Research and development expenses increased to $18.6 million from $14.3 million, while general and administrative expenses rose sharply to $10.9 million from $1.7 million due to commercial readiness costs and headcount growth. The company ended the quarter with $819.9 million in cash, cash equivalents, and marketable securities, following a follow-on offering that raised approximately $472.0 million in May 2026. Clinically, Veradermics completed enrollment for its registration-directed Phase 2/3 Study '306' evaluating VDPHL01 in female pattern hair loss, with topline data expected in the first half of 2027. Topline results from the confirmatory Phase 3 Study '304' in men and 12-month data from Study '302' are anticipated in the second half of 2026. Veradermics is a late-stage biopharmaceutical company developing innovative therapeutics for pattern hair loss.

Veradermics, Inc. announced positive topline results from its Phase 2 'Study 207' clinical trial evaluating VDPHL01, an extended-release oral minoxidil formulation, for females with mild-to-moderate pattern hair loss. In the 6-month assessment, female participants receiving 4.5 mg doses once or twice daily showed an average non-vellus hair count increase of 22.7 hairs/cm² and 23.3 hairs/cm², respectively. Additionally, 88.9% of the once-daily arm and 90.0% of the twice-daily arm reported improved or much improved hair coverage on the Androgenetic Alopecia Impact Rating Scale. The treatment was generally well tolerated with no treatment-related serious adverse events or cardiac-related adverse events of special interest. Veradermics is a biotechnology company developing hair loss treatments.